Efficient RNA drug delivery using red blood cell extracellular vesicles
Waqas Muhammad Usman1, Tin Chanh Pham1, Yuk Yan Kwok2
1Department of Biomedical Sciences, College of Veterinary Medicine and Life Sciences, City University of Hong Kong, 83 Tat Chee Avenue, Kowloon, Hong Kong.
Nature Communications
|June 17, 2018
Summary
Red blood cell-derived extracellular vesicles (RBCEVs) offer a novel solution for RNA drug delivery, overcoming issues of low efficiency and high toxicity seen with current methods. This approach enables effective microRNA inhibition and genome editing without observable cytotoxicity.
Area of Science:
- Biotechnology
- Drug Delivery
- Molecular Biology
Background:
- Current RNA drug delivery methods face challenges with clinical application, including poor cellular uptake and significant cytotoxicity.
- Extracellular vesicles (EVs) are promising natural carriers for intercellular communication but face limitations in source availability and safety.
- Human red blood cells (RBCs), particularly Group O, present an ideal source for large-scale EV production due to universal compatibility and absence of DNA.
Purpose of the Study:
- To develop and validate a scalable method for producing RBC-derived EVs (RBCEVs) for RNA drug delivery.
- To assess the efficacy of RBCEVs in delivering various RNA therapeutics, including antisense oligonucleotides, Cas9 mRNA, and guide RNAs.
- To evaluate the safety and therapeutic potential of RBCEVs in preclinical models.
Main Methods:
- Generation of large-scale quantities of extracellular vesicles from human red blood cells (RBCs).
- Loading of RNA drugs, such as antisense oligonucleotides, Cas9 mRNA, and guide RNAs, into RBCEVs.
- In vitro testing of RBCEV-mediated RNA drug delivery in human cells.
- In vivo testing of RBCEV-mediated RNA drug delivery in xenograft mouse models.
Main Results:
- Successful production of substantial amounts of RBC-derived EVs (RBCEVs).
- Demonstrated robust microRNA inhibition using RBCEV-delivered RNA therapeutics.
- Achieved effective CRISPR-Cas9 genome editing in human cells and mouse models via RBCEV delivery.
- Observed no significant cytotoxicity associated with RBCEV-mediated RNA drug delivery.
Conclusions:
- RBC-derived EVs provide a safe and scalable platform for delivering RNA-based therapeutics.
- RBCEVs overcome key limitations of existing RNA drug delivery systems, enhancing therapeutic potential.
- This novel strategy holds promise for advancing RNA drug therapies for clinical applications.
Related Concept Videos
01:16Drug Delivery: Overview
891
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
891
01:18Drug Delivery: Enteral Route
1.8K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.8K
01:29Drug Delivery: Parenteral Route
1.8K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.8K
01:22Drug Delivery: Miscellaneous Routes
836
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
836
01:30Drug Binding to Blood Components
539
When drugs enter systemic circulation, they interact with various components of the blood, including proteins such as human serum albumin (HSA), α1-acid glycoprotein (AAG), lipoproteins, globulins, and red blood cells (RBCs).
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...
539
01:23Red Algae
1.0K
Red algae, also known as rhodophytes, are primarily found in marine environments, though some species inhabit freshwater and terrestrial ecosystems. These organisms exist in both unicellular and multicellular forms, with some multicellular varieties reaching macroscopic sizes.As phototrophic organisms, red algae contain chlorophyll a; however, their chloroplasts lack chlorophyll b. Instead, they possess phycobiliproteins, which serve as major light-harvesting pigments, similar to those found in...
1.0K